

Frederik Persson

List of Publications by Citations

Source: <https://exaly.com/author-pdf/594689/frederik-persson-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136
papers

6,898
citations

37
h-index

82
g-index

148
ext. papers

8,684
ext. citations

6.9
avg, IF

5.69
L-index

#	Paper	IF	Citations
136	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020 , 41, 255-323	9.5	1360
135	Cardiorenal end points in a trial of aliskiren for type 2 diabetes. <i>New England Journal of Medicine</i> , 2012 , 367, 2204-13	59.2	893
134	Aliskiren combined with losartan in type 2 diabetes and nephropathy. <i>New England Journal of Medicine</i> , 2008 , 358, 2433-46	59.2	882
133	Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 709-717	18.1	208
132	Urinary proteomics for early diagnosis in diabetic nephropathy. <i>Diabetes</i> , 2012 , 61, 3304-13	0.9	191
131	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 1999-2010	12.7	164
130	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012 , 42, 1027-36	4.6	131
129	Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. <i>Diabetes Care</i> , 2009 , 32, 1873-9	14.6	124
128	Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 344-351	6.7	124
127	Diagnosis of diabetic kidney disease: state of the art and future perspective. <i>Kidney International Supplements</i> , 2018 , 8, 2-7	6.3	117
126	A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. <i>Diabetologia</i> , 2013 , 56, 259-67	10.3	117
125	YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. <i>Diabetes Care</i> , 2009 , 32, 323-8	14.6	107
124	Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. <i>Kidney International</i> , 2008 , 73, 1419-25	9.9	102
123	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 1563-70	4.3	94
122	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in TType 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. <i>BMJ Open</i> , 2016 , 6, e010310	3	92
121	Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 751-759	6.9	89
120	Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. <i>Diabetes Care</i> , 2013 , 36, 715-21	14.6	78

119	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 301-312	18.1	75
118	Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008 , 68, 731-8	2	66
117	Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. <i>Diabetes</i> , 2006 , 55, 3550-5	0.9	66
116	Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. <i>Diabetic Medicine</i> , 2012 , 29, e184-90	3.5	61
115	Microalbuminuria: a parameter that has changed diabetes care. <i>Diabetes Research and Clinical Practice</i> , 2015 , 107, 1-8	7.4	58
114	The effect of liraglutide on renal function: A randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 239-247	6.7	55
113	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1700-1711	4.3	52
112	Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. <i>Kidney International</i> , 2017 , 91, 982-988	9.9	51
111	Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function-Even Without Albuminuria. <i>Diabetes Care</i> , 2019 , 42, 1886-1894	14.6	51
110	Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. <i>Diabetic Medicine</i> , 2015 , 32, 343-52	3.5	49
109	Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. <i>Diabetes Care</i> , 2010 , 33, 2304-9	14.6	49
108	Tissue Renin-Angiotensin systems: a unifying hypothesis of metabolic disease. <i>Frontiers in Endocrinology</i> , 2014 , 5, 23	5.7	48
107	initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. <i>Diabetes Care</i> , 2011 , 34, 2078-83	14.6	48
106	Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 670-4	3.2	47
105	Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1866-1873	4.3	47
104	Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 1025-31	6.9	46
103	Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012 , 13, 387-93	3	45
102	Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 169-77	6.7	44

101	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 2079-2089	4.3	44
100	Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	37
99	High YKL-40 levels predict mortality in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012 , 96, 84-9	7.4	35
98	Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2016 , 17,	3	33
97	Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 901-905	6.7	31
96	Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 309-17	18.1	31
95	Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. <i>Cardiovascular Diabetology</i> , 2017 , 16, 88	8.7	27
94	Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. <i>Diabetologia</i> , 2010 , 53, 1576-80	10.3	26
93	Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium-Glucose Cotransporter 2 Inhibitors-A Nationwide, Retrospective Cohort Study, 1995-2014. <i>Diabetes Care</i> , 2017 , 40, e57-e58	14.6	24
92	Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives. <i>Nephrologie Et Therapeutique</i> , 2018 , 14 Suppl 1, S31-S37	0.6	24
91	Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. <i>Diabetologia</i> , 2009 , 52, 46-9	10.3	24
90	Effect of large weight reductions on measured and estimated kidney function. <i>BMC Nephrology</i> , 2017 , 18, 52	2.7	23
89	Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - An observational follow-up study. <i>PLoS ONE</i> , 2018 , 13, e0196634	3.7	23
88	Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?. <i>Journal of Hypertension</i> , 2013 , 31, 1646-52	1.9	23
87	Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 296-303	4.3	22
86	24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2013 , 12, 122	8.7	22
85	Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 3242-9	4.3	22
84	The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1921-1929	14.6	21

83	Ambulatory tonometric blood pressure measurements in patients with diabetes. <i>Diabetes Technology and Therapeutics</i> , 2012 , 14, 453-6	8.1	21
82	Development and validation of a brief, descriptive Danish pain questionnaire (BDDPQ). <i>Acta Anaesthesiologica Scandinavica</i> , 2004 , 48, 486-90	1.9	21
81	Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1112-1119	14.6	19
80	Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 410-6	6.9	19
79	Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012 , 13, 118-21	3	19
78	Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. <i>Diabetic Medicine</i> , 2018 , 35, 1375-1382	3.5	19
77	A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 434-41	3.9	18
76	Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2013 , 14, 161-6	3	18
75	Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. <i>Endocrinology, Diabetes and Metabolism</i> , 2018 , 1, e00036	2.7	18
74	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. <i>Proteomics</i> , 2013 , 13, 2967-75	4.8	17
73	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. <i>Kidney International</i> , 2017 , 92, 1242-1248	9.9	17
72	Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 837-846	18.1	17
71	Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. <i>Acta Diabetologica</i> , 2018 , 55, 1143-1150	3.9	15
70	Variability in response to albuminuria-lowering drugs: true or random?. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1197-1204	3.8	14
69	Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. <i>Diabetologia</i> , 2017 , 60, 1883-1891	10.3	14
68	Urinary albumin and 8-oxo-7,8-dihydroguanosine as markers of mortality and cardiovascular disease during 19 years after diagnosis of type 2 diabetes - A comparative study of two markers to identify high risk patients. <i>Redox Biology</i> , 2017 , 13, 363-369	11.3	14
67	Urinary Proteomics and Precision Medicine for Chronic Kidney Disease: Current Status and Future Perspectives. <i>Proteomics - Clinical Applications</i> , 2019 , 13, e1800176	3.1	13
66	Mitigating risk of aldosterone in diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020 , 29, 145-151	3.5	12

65	Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial). <i>BMJ Open</i> , 2017 , 7, e013802	3	11
64	Interpretation of HbA in primary care and potential influence of anaemia and chronic kidney disease: an analysis from the Copenhagen Primary Care Laboratory (CopLab) Database. <i>Diabetic Medicine</i> , 2018 , 35, 1700-1706	3.5	11
63	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021 , 44, 1894-1897	14.6	11
62	The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial. <i>Diabetologia</i> , 2021 , 64, 42-55	10.3	11
61	Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 162-168	3.2	10
60	Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. <i>European Heart Journal</i> , 2020 , 41, 328	9.5	10
59	The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 1146-51	3.2	9
58	Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial. <i>BMJ Open</i> , 2016 , 6, e009134	3	9
57	Sequential RAAS blockade: is it worth the risk?. <i>Advances in Chronic Kidney Disease</i> , 2014 , 21, 159-65	4.7	8
56	Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy. <i>Diabetes Care</i> , 2011 , 34, 1192-8	14.6	8
55	Direct renin inhibition in chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2013 , 76, 580-6	3.8	8
54	Drug-drug interaction between warfarin and statins: A Danish cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 694-699	3.8	8
53	Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1804-1813	6.9	7
52	Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1261-1265	6.7	7
51	Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 1440-1442	3.2	7
50	N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2899-2904	6.7	7
49	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions. <i>PLoS ONE</i> , 2020 , 15, e0243737	3.7	7
48	Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 659-666	4.3	7

47	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2021 , 44, 1020-1026	14.6	7
46	Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107590	3.2	6
45	Serum uric acid and progression of diabetic nephropathy in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 470-473	3.2	6
44	Improving the effectiveness of short-term courses for multidisciplinary health care professionals. <i>Practical Diabetes</i> , 2015 , 32, 180-185	0.7	6
43	Postural stability after inguinal herniorrhaphy under local infiltration anaesthesia. <i>The European Journal of Surgery</i> , 2001 , 167, 449-52		6
42	Nordic Longitudinal Data from Electronic Medical Records and Full Population National Registers: Unique Opportunities for New Insights in Benefit of Diabetes Patients. <i>Value in Health</i> , 2015 , 18, A726	3.3	5
41	Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 3573-7	4.3	5
40	Linking Kidney and Cardiovascular Complications in Diabetes-Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture. <i>Diabetes</i> , 2021 , 70, 39-50	0.9	5
39	A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 901-907	14.6	5
38	Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?. <i>Journal of Nephrology</i> , 2020 , 33, 931-948	4.8	4
37	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1164-1168	3.2	4
36	No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 530-539	6.7	4
35	Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 1133-1140	3.2	4
34	Study rationale and design of the EANITATE study (EmpAgliflozin compared to NPH Insulin for sTerold diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment. <i>BMC Endocrine Disorders</i> , 2020 , 20, 86	3.3	3
33	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2077-2088	6.7	3
32	YKL-40 in dialysis patients: another candidate in the quest for useful biomarkers in nephrology. <i>Kidney International</i> , 2018 , 93, 21-22	9.9	3
31	The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial. <i>Diabetic Medicine</i> , 2018 , 35, 392-393	3.5	3
30	Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies. <i>Kidney International</i> , 2021 , 99, 768-770	9.9	3

29	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. <i>Scientific Reports</i> , 2021 , 11, 10624	4.9	3
28	Achieving a useful and person-centred diabetes consultation is a shared responsibility between diabetologists and people with diabetes: a qualitative study of perspectives from people with type 1 diabetes. <i>Diabetic Medicine</i> , 2021 , 38, e14382	3.5	3
27	Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. <i>Diabetes Care</i> , 2017 , 40, e32-e33	14.6	2
26	Effects of RAS inhibitors on diabetic retinopathy. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 315-6	18.1	2
25	Oral treatment of glucocorticoid-induced diabetes mellitus: A systematic review. <i>International Journal of Clinical Practice</i> , 2020 , 74, e13529	2.9	2
24	Lipoprotein(a) and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107593	3.2	2
23	Discrepancy between tonometric ambulatory and cuff-based office blood pressure measurements in patients with type 1 diabetes. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 686-93	2.3	2
22	Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012 , 13, 250-3	3	2
21	Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	2
20	Risk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015. <i>Primary Care Diabetes</i> , 2021 , 15, 262-268	2.4	2
19	Improving frequency of urinary albumin testing in type 2 diabetes in primary care - An analysis of cross-sectional studies in Denmark. <i>Primary Care Diabetes</i> , 2021 , 15, 1007-1011	2.4	2
18	Incidence of New-Onset Type 2 Diabetes After Cancer: A Danish Cohort Study. <i>Diabetes Care</i> , 2022 , 45, e105-e106	14.6	2
17	A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. <i>Annals of Translational Medicine</i> , 2021 , 9, 716	3.2	1
16	Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes. <i>PLoS ONE</i> , 2021 , 16, e0254859	3.7	1
15	Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes. <i>Diabetic Medicine</i> , 2021 , 38, e14459	3.5	1
14	Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin. <i>Kidney International</i> , 2019 , 95, 1287-1288	9.9	0
13	Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study. <i>Diabetic Medicine</i> , 2021 , 38, e14405	3.5	0
12	A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2354-2363	6.7	0

- 11 Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor.. *Frontiers in Pharmacology*, **2022**, 13, 799915 5.6 0
- 10 What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?. *Advances in Chronic Kidney Disease*, **2021**, 28, 290-297 4-7
- 9 Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737
- 8 Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737
- 7 Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737
- 6 Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737
- 5 Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737
- 4 Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737
- 3 Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737
- 2 Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions **2020**, 15, e0243737
- 1 Is Time-Restricted Eating Safe in the Treatment of Type 2 Diabetes? A Review of Intervention Studies. *Nutrients*, **2022**, 14, 2299 6.7